±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 608  |  »Ø¸´: 1

yw-cell

гæ (³õÈëÎÄ̳)

[½»Á÷] ±±¾©´óѧ֣Ïþ·åÍŶÓÀûÓÃTALEN¼¼ÊõÑо¿HSCARG¸ºµ÷¿ØÏÈÌìÃâÒß»úÖÆ ÒÑÓÐ1È˲ÎÓë

¡¡¡¡±±¾©´óѧÉúÃü¿ÆÑ§Ñ§ÔºÖ£Ïþ·å½ÌÊÚÑо¿×éÔÚ¡¶PLOS Pathogen¡··¢±íÌâΪ¡°HSCARG negatively regulates the cellular antiviral RIG-I like receptor signaling pathway by inhibiting TRAF3 Ubiquitination via recruiting OTUB1¡±µÄÂÛÎÄ¡£Ñо¿½á¹û±íÃ÷£¬HSCARGµÄ¾«È·¿ØÖÆÊÇÒ»ÖÖз¢ÏֵĿ¹²¡¶¾ÏÈÌìÃâÒ߸º·´À¡µ÷½Ú»úÖÆ£¬Òò´ËHSCARGÊÇÒ»¸öDZÔÚµÄÑ×Ö¢ºÍ×ÔÉíÃâÒßÐÔ¼²²¡µÄ»ùÒò°Ðµã¡£
¡¡¡¡ÏÈÌìÃâÒßÊÇÉúÎïÌå¶Ô¿¹Ö²¡²¡Ô­ÌåÈ粡¶¾¡¢Ï¸¾ú¡¢¼ÄÉú³æµÄµÚÒ»µÀ·ÀÏß¡£Ï¸°û¿¹²¡¶¾·´Ó¦µÄºËÐÄÊǸÉÈÅËØµÄÉú²ú¡£¸ºÔðʶ±ðÃâÒ߯½ºâµÄ¼à¹Ü»úÖÆÓÈÎªÖØÒª£¬Ëü¿ÉÒԼලÃâÒß·´Ó¦µÄÒì³£»î¶¯µ¼ÖµÄÃâÒßȱÏÝ»ò×ÔÉíÃâÒßÐÔ¼²²¡¡£Ô½À´Ô½¶àµÄÖ¤¾Ý±íÃ÷£¬·ºËØ»¯ÔÚµ÷½Ú²¡¶¾´¥·¢£¬¸ÉÈÅËØ²úÉúµÈ¹ý³ÌÖÐÆð׏ؼüµÄ×÷Óᣱ¾Ñо¿·¢ÏÖHSCARGͨ¹ý=OTUB1£¬ÒÖÖÆTRAF3·ºËØ»¯£¬µ¼ÖÂÏÂÓÎIKKEºÍIRF3»î¶¯Õϰ­£¬´Ó¶ø¸ºµ÷¿ØÏ¸°ûÄÚ¿¹²¡¶¾RIG-1ÑùÊÜÌåÐźÅͨ·¡£RIG-IÑùÊÜÌ壨RLRs£©¿ÉÒÔͨ¹ýʶ±ðϸ°ûÖÊÄÚ²¡¶¾RNAÀ´Æô¶¯ÏÈÌìÃâÒß¡£ËüÃÇ¿Éͨ¹ýÔö¼ÓIFNˮƽ¡¢×ªÂ¼Ò»ÏµÁп¹²¡¶¾»ùÒòµÈ·½Ê½£¬À´±£»¤ËÞÖ÷¡£±¾Ñо¿·¢ÏÖHSCARGÊÇNF-¦ÊBµÄ¸ºÏòµ÷¿ØÒò×Ó£¬¿É²ÎÓëÏÈÌìÃâÒß¹ý³Ì¡£
¡¡¡¡ÊµÑéÖÐÀûÓÃCre/ loxPϵͳ£¬ÔÚHSCARG»ùÒò´¦²åÈë¶îÍâÖÕÖ¹×ÓÒÔ¼°ÔÚµÚËÄÍâÏÔ×ÓÄÚ²åÈë¶îÍâÐòÁУ¬ÈÅÂÒHSCARG·­Òë¡£ÔÚ´ËʵÑé¹ý³ÌÖÐʹÓÃÉϺ£Ë¹µ¤ÈüÉúÎï¼¼Êõ¹«Ë¾µÄ²úÆ·Fast TALE™ TALEN kit£¨SIDANSAI£©¡£¸Ã²úÆ·ÒÑ»ñµÃרÀûÊÚȨ¡£TALEN ¼¼Êõ£¨Transcription activator¨Clike effector Nuclease£©ÊÇÒ»ÖÖеİÐÏò»ùÒòÐÞÊμ¼Êõ£¬TALEµ°°×µÄ°±»ùËáÐòÁÐÓë°ÐλµãµÄºËËáÐòÁоßÓй̶¨µÄÒ»Ò»¶ÔÓ¦¹ØÏµ¡£Ñо¿Õß¿Éͨ¹ý×éºÏ¸÷ÀàÄ£¿é£¬¿ÉÕë¶ÔÈÎÒâºËËá°ÐÐòÁй¹½¨TALEN£¬ÔÚÌØÒìλµãÇиîÄ¿±ê»ùÒò£¬²úÉúË«Á´¶ÏÁÑ£¬½ø¶ø¶Ô¸Ãλµã½øÐжàÖÖDNA²Ù×÷£¬Èç»ùÒòÇóý¡¢»ùÒòÇÃÈë¡¢¶¨µãÍ»±ä¡£¸Ã¼¼Êõ³É¹¦½â¾öÁËRNAi¼¼ÊõÖÐKnockdownЧÂʵÍϵÄÎÊÌ⣬ͬʱ¿Ë·þÁËпָºËËáø£¨ZFN£©¼¼Êõɸѡ¸´ÔÓ¡¢³É±¾¹ý¸ßµÄȱµã£¬Ò²±ÜÃâÁËCRISPR/Cas9ÑÏÖØµÄÍѰÐÏÖÏó£¬Ê¹°ÐÏò»ùÒòÐÞÊαäµÃ¸üΪ¸ßЧºÍ±ã½Ý¡£TALEN¼¼ÊõÏÖÒѳɹ¦Ó¦ÓÃÓÚ¶¯ÎÈËÀà¡¢Êó¡¢°ßÂíÓã¡¢¼Ò²ÏµÈ£©¡¢Ö²ÎÑ̲ݡ¢Ë®µ¾¡¢ÄâÄϽæµÈ£©¡¢Î¢ÉúÎ½Íĸ¡¢²¡¶¾µÈ£©£¬ÎÞ»ùÒòÐòÁС¢Ï¸°ûÀàÐͺÍÎïÖֵȵÄÏÞÖÆ¡£¹ýÈ¥£¬½«¸ß¶ÈÖØ¸´µÄTALEÄ£¿éÁ¬½ÓÔÚÒ»ÆðÊ®·ÖÀ§ÄÑ£¬FastTALE™¼¼ÊõµÄ³öÏÖ³¹µ×½â¾öÁËÕâ¸öÄÑÌ⣬¿ÉÒÔ¼òµ¥¡¢¿ìËÙ¡¢¸ßЧµØÔÚ1ÌìÄÚÍê³ÉTALENµÄ¹¹½¨¡£
¡¡¡¡
Ô­Îijö´¦£º
PLoS Pathog. 2014 Apr 24;10(4):e1004041.
HSCARG negatively regulates the cellular antiviral RIG-I like receptor signaling pathway by inhibiting TRAF3 ubiquitination via recruiting OTUB1.
Abstract
RIG-I like receptors (RLRs) recognize cytosolic viral RNA and initiate innate immunity; they increase the production of type I interferon (IFN) and the transcription of a series of antiviral genes to protect the host organism. Accurate regulation of the RLR pathway is important for avoiding tissue injury induced by excessive immune response. HSCARG is a newly reported negative regulator of NF-¦ÊB. Here we demonstrated that HSCARG participates in innate immunity. HSCARG inhibited the cellular antiviral response in an NF-¦ÊB independent manner, whereas deficiency of HSCARG had an opposite effect. After viral infection, HSCARG interacted with tumor necrosis receptor-associated factor 3 (TRAF3) and inhibited its ubiquitination by promoting the recruitment of OTUB1 to TRAF3. Knockout of HSCARG attenuated the de-ubiquitination of TRAF3 by OTUB1, and knockdown of OTUB1 abolished the effect of HSCARG. HSCARG also interacted with Ikappa-B kinase epsilon (IKK¦Å) after viral infection and impaired the association between TRAF3 and IKK¦Å, which further decreased the phosphorylation of IKK¦Å and interferon response factor 3 (IRF3), thus suppressed the dimerization and nuclear translocation of IRF3. Moreover, knockdown of TRAF3 dampened the inhibitory effect of IFN-¦Â transcription by HSCARG, suggesting that TRAF3 is necessary for HSCARG to down-regulate RLR pathway. This study demonstrated that HSCARG is a negative regulator that enables balanced antiviral innate immunity.
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wxxwx

½ð³æ (СÓÐÃûÆø)

¹ýÑÛÔÆÑÌ£¬ÇÒÐÐÇÒ´Ò
2Â¥2014-07-08 20:54:09
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ yw-cell µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0703»¯Ñ§ +6 ÄÝÄÝninicgb 2026-03-27 6/300 2026-03-27 17:18 by shangxh
[¿¼ÑÐ] 279 ·Ö Çóµ÷¼Á +4 ˯¸öºÃ¾õ_16 2026-03-24 4/200 2026-03-27 15:05 by ×íÔÚ·çÀï
[¿¼ÑÐ] Ò»Ö¾Ô¸»ª¶«Àí¹¤´óѧ081700£¬³õÊÔ·ÖÊý271 +6 kotoko_ik 2026-03-23 7/350 2026-03-27 12:29 by »ÝÖÝÅíÓÚêÌ
[¿¼ÑÐ] 321Çóµ÷¼Á +4 è±Óñ~~ 2026-03-25 4/200 2026-03-27 11:41 by sanrepian
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á +5 .m.. 2026-03-25 5/250 2026-03-27 11:08 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 284Çóµ÷¼Á +11 junqihahaha 2026-03-26 12/600 2026-03-27 04:37 by wxiongid
[¿¼ÑÐ] 329Çóµ÷¼Á +7 Å¥¶÷Ñ© 2026-03-25 7/350 2026-03-27 04:28 by wxiongid
[¿¼ÑÐ] 317Çóµ÷¼Á +7 µ°»ÆÏÌÈâôÕ 2026-03-26 7/350 2026-03-27 02:29 by fmesaito
[¿¼ÑÐ] 343Çóµ÷¼Á +4 ÔùÎÒÒ»±¾Êé 2026-03-23 4/200 2026-03-27 00:40 by wxiongid
[¿¼ÑÐ] 349Çóµ÷¼Á +5 ½Ü˹ËþÀï˹ 2026-03-21 5/250 2026-03-27 00:31 by wxiongid
[¿¼ÑÐ] 327Çóµ÷¼Á +7 prayer13 2026-03-23 7/350 2026-03-26 20:48 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +3 µ¤ÇàÄÌ¸Ç 2026-03-26 5/250 2026-03-26 20:11 by macy2011
[¿¼ÑÐ] Çóµ÷¼Á +8 Auroracx 2026-03-22 8/400 2026-03-26 19:55 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] Ò»Ö¾Ô¸ ÄϾ©Óʵç´óѧ 288·Ö ²ÄÁÏ¿¼ÑÐ Çóµ÷¼Á +3 jl0720 2026-03-26 3/150 2026-03-26 13:39 by zzll406
[¿¼ÑÐ] 284Çóµ÷¼Á +15 Zhao anqi 2026-03-22 15/750 2026-03-25 12:51 by wht0531
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á£¬Çóµ¼Ê¦ÊÕ +7 ÌìÌìºÃÔËÀ´Éϰ¶° 2026-03-24 7/350 2026-03-24 20:26 by peike
[¿¼ÑÐ] »¯¹¤×¨Ë¶Çóµ÷¼Á +3 questionÍì·ç 2026-03-24 3/150 2026-03-24 18:48 by jhhcooi
[¿¼ÑÐ] ²ÄÁÏ/ũҵרҵ£¬07/08¿ªÍ·¾ù¿É£¬¹ýÏß¾ÍÐÐ +3 ºÇßíŶ»í 2026-03-23 4/200 2026-03-23 22:30 by Íô£¡£¿£¡
[¿¼ÑÐ] 269Çóµ÷¼Á +4 ÎÒÏë¶ÁÑÐ11 2026-03-23 4/200 2026-03-23 21:25 by pswait
[¿¼ÑÐ] 266Çóµ÷¼Á +3 ÍÛºôºßºôºß 2026-03-20 3/150 2026-03-21 16:46 by barlinike
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û